← Back to Clinical Trials
Recruiting NCT07382323

NCT07382323 Metacognitive Therapy Compared to Cognitive-behavioral Therapy

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07382323
Status Recruiting
Phase
Sponsor Karolinska Institutet
Condition Generalized Anxiety Disorder
Study Type INTERVENTIONAL
Enrollment 30 participants
Start Date 2026-01-28
Primary Completion 2026-12

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
Transdiagnostic metacognitive therapyDisorder-specific cognitive-behavioral therapy

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 30 participants in total. It began in 2026-01-28 with a primary completion date of 2026-12.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

This is a qualitative study of participants who have taken part in a randomized controlled trial comparing transdiagnostic metacognitive therapy and disorder-specific cognitive-behavioral therapy for anxiety disorders. The purpose of the study is to explore participant perceptions of the respective treatment models to facilitate implementation and dissemination of the treatments.

Eligibility Criteria

Inclusion Criteria: * Age 18 years or older, * A principal diagnosis of generalized anxiety disorder, social anxiety disorder, or posttraumatic stress disorder, * No change in dose during the last six weeks if on pharmacological treatment, and * Ability to read and speak Swedish. Exclusion Criteria: * A current diagnosis of psychotic disorder, bipolar disorder, neurocognitive disorder, or moderate to severe substance use disorder, * Acute suicide risk, or * Concurrent psychological treatment.

Contact & Investigator

Central Contact

Benjamin Bohman

✉ benjamin.bohman@ki.se

📞 0701713443

Principal Investigator

Benjamin Bohman

PRINCIPAL INVESTIGATOR

Karolinska Institutet

Frequently Asked Questions

Who can join the NCT07382323 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Generalized Anxiety Disorder. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07382323 currently recruiting?

Yes, NCT07382323 is actively recruiting participants. Contact the research team at benjamin.bohman@ki.se for enrollment information.

Where is the NCT07382323 trial being conducted?

This trial is being conducted at Stockholm, Sweden.

Who is sponsoring the NCT07382323 clinical trial?

NCT07382323 is sponsored by Karolinska Institutet. The principal investigator is Benjamin Bohman at Karolinska Institutet. The trial plans to enroll 30 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology